FDA Lifts Urological Surgical Restriction for Medafor’s Arista™AH Absorbable Surgical Hemostat

MINNEAPOLIS, July 16, 2007 -- Medafor, Inc., announced today that its Arista™AH Absorbable Hemostat is now available for use in urological surgical procedures. The FDA has removed the restriction on this application of Arista AH from the device indication statement. READ FULL STORY.

2007

2006

2003

2002

2001

2000

Chicago, Illinois
112th Annual Meeting and OTO Expo, American Academy of Otolaryngology
September 21-24, 2008

San Francisco, California
94th Annual Clinical Congress, American College of Surgeons
October 12-16, 2008

HOME | ABOUT MEDAFOR | PRODUCTS | TECHNOLOGY | RESEARCH | MEDIA CENTER | CONTACT US

Medafor, Inc., was founded in 1999 to develop and market applications for its patented MPH® (Microporous Polysaccharide Hemospheres Technology). Statements presented on this page have not been evaluated by the U.S. FDA. See respective Instructions for Use for product applications and indications. Site content and images Copyright 2008 Medafor, Inc. All Rights Reserved. No part of this site may be copied, republished, excerpted or transferred to other media without the express written consent of Medafor, Inc. Arista™AH, MPH®, Medafor®, MPatcH®, FlexiTip™ are trademarks of Medafor, Inc. Other trademarks mentioned are the property of their respective companies. For information, contact Medafor at 1-763-571-6300.